Nephros (NEPH) Expected to Post Quarterly Earnings on Thursday

Nephros (NASDAQ:NEPH) is expected to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Nephros to post earnings of $0.01 per share and revenue of $4.9940 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Nephros (NASDAQ:NEPH) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, hitting the consensus estimate of $0.01. Nephros had a return on equity of 7.66% and a net margin of 4.06%.The company had revenue of $5.21 million for the quarter, compared to the consensus estimate of $5.02 million. On average, analysts expect Nephros to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Nephros Stock Down 7.4%

Shares of NEPH stock opened at $3.24 on Thursday. Nephros has a 12 month low of $2.66 and a 12 month high of $6.42. The firm has a market cap of $35.19 million, a PE ratio of 46.29 and a beta of 1.49. The stock has a 50 day moving average of $3.48 and a 200-day moving average of $3.56.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Zacks Research upgraded shares of Nephros to a “hold” rating in a research note on Monday, July 20th. Weiss Ratings downgraded shares of Nephros from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, July 17th. Finally, Northland Securities initiated coverage on shares of Nephros in a research report on Friday, July 17th. They set a “market perform” rating and a $4.00 price objective for the company. One equities research analyst has rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $5.00.

Institutional Investors Weigh In On Nephros

A number of hedge funds have recently made changes to their positions in the company. Topline Capital Management LLC grew its stake in Nephros by 13.1% during the second quarter. Topline Capital Management LLC now owns 477,449 shares of the company’s stock worth $1,953,000 after buying an additional 55,360 shares during the last quarter. Quadrature Capital Ltd bought a new position in shares of Nephros in the fourth quarter valued at approximately $112,000. Marshall Wace LLP bought a new position in shares of Nephros in the fourth quarter valued at approximately $107,000. Renaissance Technologies LLC grew its position in Nephros by 25.8% during the 4th quarter. Renaissance Technologies LLC now owns 103,772 shares of the company’s stock worth $506,000 after acquiring an additional 21,272 shares during the last quarter. Finally, Essex Investment Management Co. LLC raised its position in Nephros by 57.1% in the 4th quarter. Essex Investment Management Co. LLC now owns 38,984 shares of the company’s stock valued at $190,000 after purchasing an additional 14,162 shares during the last quarter. Institutional investors and hedge funds own 41.10% of the company’s stock.

About Nephros

Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.